Aims A randomized trial was performed to assess the safety and efficacy of a laser guidewire, in the treatment of chronic coronary occlusions.
Introduction
Since the introduction of percutaneous transluminal coronary angioplasty (PTCA), recanalization of chronically occluded coronary arteries has been recognised as a true challenge. Consecutive series of patients treated with various guidewire technologies have been reported by a large number of investigators. Typically, the success rates in most reports were less than favourable, the most common reason for failure being the inability to pass a guidewire through the occlusion into the distal true lumen [1, 2] . As several reports have demonstrated the clinical relevance of successful recanalization of occluded coronary arteries [3] [4] [5] [6] [7] [8] , further exploration and improvement of percutaneous techniques seemed justifiable. As a result, a laser wire (laser guidewire), the Spectranetics Prima Coronary Total Occlusion System Model 018-003 (Spectranetics, Colorado Springs, CO, U.S.A.) was developed. Following a single centre pilot study [9] , and the European-and US multicentre registries [10, 11] , a multicentre randomized controlled clinical trial was performed. Here we report on the final results of the randomized trial. 
Methods

Patient selection
From May 1995 until June 1997, a multicentre randomized controlled clinical trial was conducted in 18 European centres. A total of 303 patients with angina and/or objective evidence of ischaemia and a TIMI 0 flow [12] occlusion, of more than 4 weeks duration, as proven with prior coronary angiography, were included in the study. Angiographic exclusion criteria consisted of: less than Rentrop Classification [13] Grade 2 visualization of the distal lumen via collaterals; an occluded ostium of the right coronary artery or the main stem of the left coronary artery; a non-visible entry point of the target lesion; more than one anatomical curve expected within the missing segment of the vessel; or angiographic evidence of thrombus in the target occlusion. The study had the approval of the local Ethical Review Committees. Written informed consent was obtained from all patients enrolled in the study.
Study design and end-points
The primary objective of the study was to evaluate the safety and efficacy of crossing a chronic coronary occlusion using the laser guidewire as compared to 'conventional' mechanical guidewires. The primary endpoint was treatment success, defined as reaching the true lumen distal to the occlusion within 30 min of fluoroscopic time. This had to be angiographically documented by an antegrade or retrograde filling of the distal segment showing the tip of the wire in the true lumen. In case of failure, the study protocol allowed for a crossover to the non-allocated guidewire for a second attempt. The duration of the additional attempt was also restricted to 30 min of fluoroscopic time. Clinical follow-up was performed at 1, 6 and 12 months. Routine angiographic follow-up of those patients who underwent successful angioplasty was carried out at the 6-month visit. Diagnostic angiography before the procedure, after the procedure and at the 6-month follow-up was performed according to standard angiographic acquisition procedures for quantitative coronary angiographic (quantitative coronary angiography) analysis [14] .
Secondary objectives
Secondary objectives were to establish the safety and efficacy of the laser compared to the mechanical guidewire within 1, 6 and 12 months after the initial crossing and adjunctive angioplasty; to investigate the efficacy and safety of crossover treatment after an initial unsuccessful attempt with the allocated guidewire; to investigate the patency of the target vessel and restenosis of the recanalized target vessel within 6 months after treatment; to investigate event-free survival rate and anginal status within 12 months after treatment; and to explore resource utilization of the procedure, which consisted of procedure time, procedure related materials (catheters, angioplasty devices and contrast medium used) and length of hospital stay.
Definitions
Procedural success was defined as an average diameter stenosis of less than 50% in two orthogonal views. Clinical success was defined as procedural success without death, myocardial infarction, coronary artery bypass surgery (CABG), tamponade or repeat angioplasty during the index hospital stay. Safety was evaluated on the occurrence of perforation of the vessel wall, defined as leakage of contrast dye into the pericardial space, or tamponade necessitating either medical treatment, pericardiocentesis with drainage or thoracotomy. Major adverse cardiac event-free survival was defined as freedom from cardiac death, myocardial infarction, or revascularization of the target vessel (PTCA and/or CABG). All deaths were considered cardiac unless otherwise documented. All myocardial infarctions were counted as events, whether or not they were associated with angioplasty or CABG. A positive diagnosis of myocardial infarction was made if one of the following criteria was met: development of new abnormal Q waves not present on the patient's baseline ECG (i.e. before randomization), enzyme changes defined by more than twice the upper limit of normal of creatine kinase and the presence of creatine kinase MB (i.e. greater than the upper normal limit for the appropriate laboratory). A non-Q wave myocardial infarction was defined as enzyme changes defined by more than twice the upper limit of normal of creatine kinase and the presence of creatine kinase MB (i.e. greater than the upper normal limit for the appropriate laboratory) without the development of new abnormal Q waves. Elective repeat angioplasty or CABG during follow-up was preceded by an exercise tolerance test showing anginal complaints and/or objective evidence of ischaemia. In addition, coronary angiography was performed to indicate a diameter stenosis greater than 50% (visual assessment).
Treatments
The laser guidewire consisted of a 0·018 inch shapeable guidewire containing 12 silica fibres with a 45-micron diameter. The supplied support catheter had a 2·5 French tapered tip providing additional coaxial back-up support. The guidewire was designed to function as an exchange guidewire. The laser was a Spectranetics CVX 300 XeCl excimer laser. The fluence typically used during a laser guidewire procedure was 60 mJ . mm 2 , with a pulse repetition rate of 25 Hz. On encountering resistance with the guidewire, the laser was activated in pulse trains for a maximum of 5 s. During laser activation, the laser guidewire was advanced at a rate of approximately 1 mm per second, usually during a simultaneous injection of contrast medium in the contralateral coronary artery, if applicable. Simultaneous biplane right and left coronary angiography was recommended to assess the alignment of the laser guidewire with the segment to be crossed. Whenever the laser guidewire encountered intraluminal resistance during laser activation (for instance in more calcified lesions) the pulse repetition rate was increased to 40 Hz, thus increasing the ablation rate. The choice of mechanical guidewire and the type of adjunctive angioplasty were left to the discretion of the investigators.
Data management and trial organization
Cardialysis BV, based at Rotterdam, the Netherlands, was the Data Co-ordinating Centre. The randomization procedure was pre-defined and the balance between treatments within the centres was obtained by randomizing in blocks. Patients were randomized through a Central Telephone Allocation Service, which was provided with a complete randomization list before recruitment of the first patient. An independent Angiographic Core Laboratory, based at Cardialysis BV, was responsible for confirming all angiographic components of the primary and secondary end-points and for the quantitative analysis of the post-procedure and 6 month follow-up angiograms. Compliance with the angiographic criteria was assessed by the Angiographic Core Laboratory and adjudicated by an Angiographic Committee not blinded to the treatment assignment. Protocol violations were documented as such.
Power calculations and statistical analysis
The power calculations were based on a success rate of 60% in the mechanical wire treated patients and a type I error level of 0·05 (two-sided). With 320 patients, the trial had a power of 91% to detect an increase in success rate to 77·5% in the laser guidewire treated group, and a power of 79% to detect an increase to 75%. The Data Safety Monitoring Committee reviewed the efficacy and safety data after 160 patients had been enrolled in the study. Two types of statistical analysis were pre-specified according to the protocol and study design. The first analysis included all randomized patients (intention to treat analysis). The second analysis included only those patients who actually fulfilled the angiographic inclusion and exclusion criteria of the study (per protocol analysis). Continuous variables were tested with the Student's t-test. For categorical variables the chi-square test (without continuity correction) was used. Event-free survival distributions were estimated according to the KaplanMeier method and tested with the Log-Rank test. As there was only one primary end-point, no correction for multiple comparisons was made.
Results
Between March 1995 and June 1997 a total number of 303 patients were randomized in 18 European centres. The enrolment per centre was c10 patients in seven centres, 11-20 patients in six centres and 20-50 patients in five centres. The baseline demographic and lesion characteristics are shown in Table 1 . The majority of patients had stable angina (73%), while 56% had suffered from a previous myocardial infarction. The median angiographic age of occlusion was 9 weeks in both study arms (Fig. 1) . According to the clinical history the Table 2 , the crossing success in the laser group and the mechanical group are listed according to an intention-to-treat analysis. The difference in primary success rate between the laser and the mechanical wire (treatment success) did not reach statistical significance (53% vs 47%, P=0·33). The procedure was discontinued after a failed initial attempt in 17% (laser) and 11% (mechanical) of cases. The reasons for failure with the allocated wire are listed in Table 3 . The most frequent reason for failure observed in the laser group was misalignment (10·8%) and false route tracking (15·1%), whereas in the mechanical group the most common reason for failure was nonprogression of the wire (29·6%). Guidewire perforation was seen in a similar proportion of cases in both study arms (7·2% for the laser vs 8·8% for the mechanical guidewire). The rate of perforation in the entire patient cohort (successful and unsuccessful) was 14% (laser) and 10% (mechanical). A second attempt using the nonallocated guidewire was performed in 31% (laser) and 42% (mechanical). The success rate of an additional attempt after crossover to the laser guidewire was 45% (30 out of 66), while in the initially laser-treated group the success rate after crossover to a mechanical guidewire was 27% (12 out of 44, P=0·054). Including all attempts with non-allocated guidewires ('crossover') the overall success rate was 63% in the laser group and 66% in the mechanical group (P=0·61). In the laser guidewire group, following successful recanalization (n=91) angioplasty was successful in 79. In the mechanical guidewire group, angioplasty was successful in 100 out of 105 patients following successful guidewire crossing. As a result, clinical success was achieved in 51% (laser) and 60% (mechanical) respectively (P=0·12).
Long-term clinical follow-up according to randomization
The composite end-point and the itemized events at 400 days (laser vs mechanical) are given in Table 4a . The 
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angina-and major adverse cardiac event free survival, as shown by the Kaplan-Meier curves in Fig. 2 , show no significant difference in clinical outcome between the two groups (Log-Rank test: P=0·11, chi-square test: P=0·17). Table 4b outlines the major adverse cardiac event and anginal status at the 12-month follow-up for the patients with successful PTCA vs unsuccessful PTCA. Angina and major adverse cardiac event free survival, as shown by the Kaplan-Meier curves in Fig. 2 show that patients with successful angioplasty (n=179) had an angina and a major adverse cardiac event free survival rate of 35·2%, while in patients with failed recanalization (n=124) this rate was 17·7% (Log-Rank test: P<0·001, chi-square test: P<0·001). This significant difference is mainly ascribed to a 33% incidence of surgery in the failed recanalization group. In addition, 45·8% of patients were angina free in the successfully treated group vs 25% in the failed recanalization group.
Long-term clinical follow-up according to success of recanalization
Angiographic end-points
Following successful recanalization in 179 patients, a routine 6-month angiographic follow-up was performed in 147 (82%). Table 5 describes the result of the quantitative coronary angiography measurements. Immediately post-procedure, the minimal lumen diameter in the laser guidewire group was slightly larger than in the mechanical guidewire group (laser vs mechanical: 2·43 0·47 mm vs 2·34 0·52 mm). However, at follow-up the minimal lumen diameter in the mechanical guidewire group was larger (mechanical vs laser: 1·52 0·87 mm vs 1·30 0·90 mm) due to a significantly larger loss in the laser guidewire group (laser vs mechanical: 1·11 0·92 mm vs 0·80 0·89 mm, P=0·04). Consequently the restenosis rate in the laser group (45·5%) was slightly, but not significantly greater than in the mechanical group (38·3%, P=0·38). The re-occlusion rates were 25·8% (laser) and 16·1% (mechanical, P=0·15), despite a liberal use of stenting in both groups (90% vs 78%, respectively).
Discussion
Study design and related issues
The TOTAL investigators did not want to conduct a major clinical study with conventional, clinical endpoints without having prior evidence of the technical superiority of the new laser guidewire. Therefore, a technical, device related primary end-point was chosen. Secondly, the investigators did not want to see their patients denied the potential benefit of a crossover design allowing the use of a laser guidewire in case of a failure with a mechanical guidewire, or vice versa. As a consequence of a crossover design, the short, medium, and long-term outcome did not reflect the initial intention-to-treat with an allocated guidewire, but would reflect the clinical outcome of a recanalization procedure obtained either with a laser guidewire, a mechanical wire or a combination of both. An intention to treat analysis was only applied during the first 30 min of fluoroscopic time. The trial was inconclusive, as the difference in primary treatment success did not reach statistical significance. A per-protocol analysis (excluding specific angiographic violation criteria) prospectively described in the trial design also failed to show a significant difference (P=0·10). It should be emphasized that, in terms of clinical outcome, a composite end-point of death, myocardial infarction, CABG and re-PTCA may not reflect the true clinical benefit of a successful vs a failed attempt at recanalization. The outcome of a failed recanalization may be accepted and may not result in an event (e.g. revascularization) although the patient remains symptomatic; conversely failed recanalization may be followed by surgical revascularization (event) with, as a consequence, alleviation of angina pectoris. An initially successful recanalization may result in the medium-term in a restenotic lesion with resurgence of angina necessitating a reintervention. Therefore, the angina and event-free survival rate was considered as a secondary end-point.
Safety issues
Despite sometimes multiple attempts at recanalization, there was no incidence of death, emergency CABG or tamponade. However, extravazation of contrast dye was seen in 13·8% of the laser guidewire group and 10·1% in the mechanical group. The most frequent reasons for laser guidewire failure were false route tracking (15·1%) and misalignment (10·8%), while the most common reason for failure in the mechanical wire group was absence of wire progression, despite mechanical manipulation (laser vs mechanical, 6·5% vs 29·6%. P=0·001). This difference is presumably related to the ablative properties of the laser guidewire. Post-procedure, the incidence of cardiac enzyme leak was not significantly different for either groups (CK>2 upper limit of normal laser vs mechanical 7·8% vs 3·6%, P=0·14). Thus, the ability to recanalize a chronic occlusion with a laser guidewire was not at the cost of an increased risk of complications. 
Angiographic follow-up
Despite a liberal use of stents (79%), the reocclusion rate for the entire study population was 20·7%. The restenosis and reocclusion rates were comparable in both study arms. The main reason for not stenting a recanalized lesion was ascribed to a combination of small vessel size (PTCA vs stent, reference diameter post procedure 2·65 mm vs 3·13 mm, P<0·01) and a low post-balloon angioplasty residual diameter stenosis (27%). Indeed, from previous studies we have learned that 'stent-like balloon angioplasty' results in a 6-month angiographic outcome comparable to post-stenting [15] [16] [17] [18] . The percentage of reocclusion was comparable to reocclusion rates for chronic occlusions, as previously reported in the literature [19, 20] . As it has been suggested that reocclusion occurs early in the course of follow-up, this could potentially be prevented by an aggressive policy of anticoagulant and antiplatelet treatment [21] .
Long term follow-up and clinical benefit
Laser wire vs mechanical wire The freedom-from-major adverse cardiac event curves (Fig. 2) indicated that the laser guidewire arm had a significantly lower major adverse cardiac event free survival at 1 year (P=0·026). This difference resulted from a higher incidence in the laser guidewire group of myocardial infarction, CABG and re-PTCA without an increase in the incidence of mortality (laser vs mechanical, 2·1% vs 4·4%, P=0·26). However, the freedom from major adverse cardiac event and angina at 1 year were similar for both groups (laser vs mechanical, 24·3% vs 31·4%, P=0·17).
Success vs failure
The freedom from major adverse cardiac event at 1 year (Fig. 2) did not differ for either successful or failed recanalization. This seeming lack of treatment efficacy was explained by an increased incidence of early CABG in the failed group (success vs failure, 12/179 (6·7%) vs 41/124 (33%), P<0·001) and a higher incidence of late re-PTCA in the successful group (success vs failure, 51/179 (28·5%) vs 10/124 (8·1%), P<0·001). As a result of vessel patency at 1 year (79·6%) the incidence of combined CABG and re-PTCA was lower in the successful PTCA group (success vs failure, 56/179 (31·3%) vs 49/124 (39·5%, P=0·14). The difference in freedom from major adverse cardiac event and angina until 1 year was statistically significant (success vs failure, 35·2% vs 17·7%, P<0·001). Also, the percentage of angina-free patients at 12 months was higher in the successful group (success vs failure, 65% vs 53%, P=0·02). With regard to the Classification of the Canadian Society of Cardiology, those patients following successful recanalization fared better (Wilcoxon RS:
P=0·023, chi-square test: P=0·04, Table 6 ). Following failed recanalization, the incidence of angina at 12 months in those patients undergoing surgery was 23·1%. In contrast, 58·2% of patients not referred to CABG were symptomatic (CABG vs no CABG, 9/39 vs 46/79, P<0·001). This would favour a policy of consequent referral for elective CABG following a failed percutaneous attempt at recanalization.
Conclusion
Although laser guidewire technology was safe, the increase in crossing success did not reach statistical significance. For the entire study population, successful PTCA improved the long-term clinical outcome (freedom from major adverse cardiac event and angina until 1 year; success vs failure, 35·2% vs 17·7%, P<0·001). However, the results of successful recanalization are still plagued by high restenosis (20·5%) and reocclusion (20·4%) rates. As a result, the 1-year clinical outcome (major adverse cardiac event-free) of the entire study population was approximately 60%. As this result is inferior to the long-term outcome of PTCA of patent stenotic lesions of similar length, a further improvement in treatment modalities aimed at reducing restenosis and/or reocclusion is needed in order to make percutaneous treatment of chronic total occlusions more efficacious. 
